Anti-SARS-CoV-2 Antibody Level among Renal Transplant Recipients: A Case Report from Nepal

Table 1

Different variables of the three renal transplant recipients.

Clinical variables	Patient 1	Patient 2	Patient 3
Age	40	38	41
Gender	Male	Male	Male
Transplant performed	2008	2005	2006
Current medications	Mycophenolate sodium 360 mg and tacrolimus 0.5 mg	Mycophenolate mofetil 500 mg and cyclosporine 25 mg	Mycophenolate mofetil 500 mg and tacrolimus (1 mg and 0.5 mg)
Body mass index	Overweight	Normal	Overweight
Comorbidities	No	No	Hypertension
1st dose COVID vaccine	16 April 2021	21 April 2021	01 June 2021
2nd dose COVID vaccine	21 June 2021	08 June 2021	08 July 2021
Serum creatinine (mg/dl)	1.3	1.4	1.2
Serum urea (mg/dl)	41.0	16.96	21.0
Sodium (Na^+) mmol/l	136	139.0	143.0
Potassium (K^+) mmol/l	4.8	3.3	4.0
Hemoglobin (g/dl)	15.8	12.6	12.7
RBC (million/mm^3)	5.48	4.64	4.76
WBC (cells/mm^3)	7900	8400	12500
Differential cell count
Neutrophil (%)	78	74	77
Lymphocyte (%)	16	21	21
Monocyte (%)	04	4	02
Eosinophil (%)	02	1	0
Basophil (%)	0	0	0
RT-PCR for COVID-19	Positive	Positive	Not tested
COVID-19 sign and symptoms	Fever, body ache, and loss of smell	Fever, malaise, sore throat, and loss of smell and taste	Unknown
Anti-SARS-CoV-2 ab (method)	18.15 COI (ECLIA)	54.5 (ELISA)	5.91 U/ml (ECLIA)
Outcome	Recovered from COVID-19	Recovered from COVID-19	Stable

Note. Morning dose; evening dose. NR: normal range; RT-PCR: reverse transcription polymerase chain reaction; ELISA: enzyme-linked immunosorbent assay; ECLIA: electrochemiluminescence immunoassay; ab: antibody; COI: cutoff index.